Results of PREVENT III: A multicenter, randomized trial of edifoligide for the prevention of vein graft failure in lower extremity bypass surgery

Journal of Vascular Surgery

Volumn 43, Issue 4, 2006, Pages

  Conte, Michael S ^a   Bandyk, Dennis F ^c   Clowes, Alexander W ^d   Moneta, Gregory L ^e   Seely, Lynn ^f   Lorenz, Todd J ^f   Namini, Hamid ^f   Hamdan, Allen D ^b   Roddy, Sean P ^g   Belkin, Michael ^a   Berceli, Scott A ^h   DeMasi, Richard J ⁱ   Samson, Russell H ^j   Berman, Scott S ^k  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^c UNIVERSITY OF SOUTH FLORIDA   (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

^e OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^f Department of Research   (United States)

^g ALBANY MEDICAL CENTER   (United States)

^h UNIVERSITY OF FLORIDA   (United States)

ⁱ Vascular and Transplant Specialists P C   (United States)

^j Sarasota Vascular Specialists   (United States)

^k Tucson Vascular Surgery   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMITOTIC AGENT; EDIFOLIGIDE; PLACEBO; UNCLASSIFIED DRUG;

ADULT; AGED; ANASTOMOSIS DEHISCENCE; ANGIOGRAPHY; ARTICLE; BLEEDING; BYPASS SURGERY; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DISEASE FREE SURVIVAL; DISEASE SEVERITY; DOPPLER ECHOGRAPHY; DOUBLE BLIND PROCEDURE; DRUG SAFETY; ECHOGRAPHY; EX VIVO STUDY; FEMALE; GRAFT FAILURE; GRAFT OCCLUSION; GRAFT PATENCY; HEALTH SURVEY; HEART ARREST; HEART INFARCTION; HIGH RISK POPULATION; HUMAN; INGUINAL REGION; KAPLAN MEIER METHOD; LEG; LEG AMPUTATION; LIMB ISCHEMIA; LIMB SALVAGE; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NECROSIS; PHASE 3 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; REVASCULARIZATION; RISK ASSESSMENT; STATISTICAL SIGNIFICANCE; STENOSIS; STROKE; SURVIVAL RATE; TRANSIENT ISCHEMIC ATTACK; VEIN GRAFT DISEASE; WOUND COMPLICATION;

EID: 33645734355     PISSN: 07415214     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jvs.2005.12.058     Document Type: Article

References (18)

1. Cox J.L., Chiasson D.A., and Gotlieb A.I. Stranger in a strange land. the pathogenesis of saphenous vein graft stenosis with emphasis on structural and functional differences between veins and arteries. Prog Cardiovasc Dis 34 (1991) 45-68
2. Conte M.S., Mann M.J., Simosa H.F., Rhynhart K.K., and Mulligan R.C. Genetic interventions for vein bypass graft disease. a review. J Vasc Surg 36 (2002) 1040-1052
3. Taylor Jr. L.M., Edwards J.M., and Porter J.M. Present status of reversed vein bypass grafting. five-year results of a modern series. J Vasc Surg 11 (1990) 193-205 discussion 205-6
4. Conte M.S., Belkin M., Upchurch G.R., Mannick J.A., Whittemore A.D., and Donaldson M.C. Impact of increasing comorbidity on infrainguinal reconstruction. a 20- year perspective. Ann Surg 233 (2001) 445-452
5. Mills J. Infrainguinal bypass. In: Rutherford R. (Ed). Vascular surgery. 6th ed. Vol 1 (2005), Elsevier Saunders, Philadelphia 1154-1174
6. Braun-Dullaeus R.C., Mann M.J., and Dzau V.J. Cell cycle progression. new therapeutic target for vascular proliferative disease. Circulation 98 (1998) 82-89
7. Bielinska A., Schivdasani R., and Zhang L. Regulation of gene expression with double-stranded phosphothioate oligonucleotides. Science 250 (1990) 997-1000
8. Mann M.J., and Conte M.S. Transcription factor decoys for the prevention of vein bypass graft failure. Am J Cardiovasc Drugs 3 (2003) 79-85
9. Morishita R., Gibbons G.H., Horiuchi M., et al. A gene therapy strategy using a transcription factor decoy of the E2F binding site inhibits smooth muscle proliferation in vivo. Proc Natl Acad Sci U S A 92 (1995) 5855-5859
10. Ehsan A., Mann M.J., Dell'Acqua G., and Dzau V.J. Long-term stabilization of vein graft wall architecture and prolonged resistance to experimental atherosclerosis after E2F decoy oligonucleotide gene therapy. J Thorac Cardiovasc Surg 121 (2001) 714-722
11. Mann M.J., Whittemore A.D., Donaldson M.C., et al. Ex-vivo gene therapy of human vascular bypass grafts with E2F decoy. the PREVENT single-centre, randomised, controlled trial. Lancet 354 (1999) 1493-1498
12. Grube E., Felderhoff T., Fitzgerald P., et al. Phase II trial of the E2F decoy in coronary bypass grafting [abstract] (2001) American Heart Association Annual Meeting (Late Breaking Clinical Trials), Anaheim, Calif
13. Conte M.S., Lorenz T.J., Bandyk D.F., Clowes A.W., Moneta G.L., and Seely B.L. Design and rationale of the PREVENT III clinical trial. edifoligide for the prevention of infrainguinal vein graft failure. Vasc Endovasc Surg 39 (2005) 15-23
14. Rutherford R.B., Baker J.D., Ernst C., et al. Recommended standards for reports dealing with lower extremity ischemia. revised version. J Vasc Surg 26 (1997) 517-538
15. Morgan M.B., Crayford T., Murrin B., and Fraser S.C. Developing the Vascular Quality of Life Questionnaire. a new disease-specific quality of life measure for use in lower limb ischemia. J Vasc Surg 33 (2001) 679-687
16. Conte M.S., Bandyk D.F., Clowes A.W., Moneta G.L., Namini H., and Seely L. Risk factors, medical therapies and perioperative events in limb salvage surgery. observations from the PREVENT III multicenter trial. J Vasc Surg 42 (2005) 456-464 discussion 464-5
17. Mann M.J., Gibbons G.H., Hutchinson H., et al. Pressure-mediated oligonucleotide transfection of rat and human cardiovascular tissues. Proc Natl Acad Sci U S A 96 (1999) 6411-6416
18. Alexander J.H., Hafley G., Harrington R.A., et al. Efficacy and safety of edifoligide, an E2F transcription factor decoy, for prevention of vein graft failure following coronary artery bypass graft surgery. PREVENT IV-a randomized controlled trial. JAMA 294 (2005) 2446-2454